Pesquisa | BVS Doenças Infecciosas e Parasitárias

1.

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.

Eron, Joseph J; Young, Benjamin; Cooper, David A; Youle, Michael; Dejesus, Edwin; Andrade-Villanueva, Jaime; Workman, Cassy; Zajdenverg, Roberto; Fätkenheuer, Gerd; Berger, Daniel S; Kumar, Princy N; Rodgers, Anthony J; Shaughnessy, Melissa A; Walker, Monica L; Barnard, Richard J O; Miller, Michael D; Dinubile, Mark J; Nguyen, Bach-Yen; Leavitt, Randi; Xu, Xia; Sklar, Peter.

Lancet ; 375(9712): 396-407, 2010 Jan 30.

Artigo em Inglês | MEDLINE | ID: mdl-20074791

2.

Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.

Zolopa, Andrew R; Berger, Daniel S; Lampiris, Harry; Zhong, Lijie; Chuck, Steven L; Enejosa, Jeffrey V; Kearney, Brian P; Cheng, Andrew K.

J Infect Dis ; 201(6): 814-22, 2010 Mar 15.

Artigo em Inglês | MEDLINE | ID: mdl-20146631

3.

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.

Lennox, Jeffrey L; DeJesus, Edwin; Lazzarin, Adriano; Pollard, Richard B; Madruga, Jose Valdez Ramalho; Berger, Daniel S; Zhao, Jing; Xu, Xia; Williams-Diaz, Angela; Rodgers, Anthony J; Barnard, Richard J O; Miller, Michael D; DiNubile, Mark J; Nguyen, Bach-Yen; Leavitt, Randi; Sklar, Peter.

Lancet ; 374(9692): 796-806, 2009 Sep 05.

Artigo em Inglês | MEDLINE | ID: mdl-19647866

4.

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.

Nadler, Jeffrey P; Berger, Daniel S; Blick, Gary; Cimoch, Paul J; Cohen, Calvin J; Greenberg, Richard N; Hicks, Charles B; Hoetelmans, Richard M W; Iveson, Kathy J; Jayaweera, Dushyantha S; Mills, Anthony M; Peeters, Monika P; Ruane, Peter J; Shalit, Peter; Schrader, Shannon R; Smith, Stephen M; Steinhart, Corklin R; Thompson, Melanie; Vingerhoets, Johan H; Voorspoels, Ellen; Ward, Douglas; Woodfall, Brian.

AIDS ; 21(6): F1-10, 2007 Mar 30.

Artigo em Inglês | MEDLINE | ID: mdl-17413684

5.

Endoscopic Third Ventriculostomy in Patients with Neurofibromatosis Type 1: A Multicenter International Experience.

Roth, Jonathan; Ber, Roee; Wisoff, Jeffrey H; Hidalgo, Eveline T; Limbrick, David D; Berger, Daniel S; Thomale, Ulrich W; Schulz, Matthias; Cinalli, Giuseppe; Santoro, Claudia; Constantini, Shlomi.

World Neurosurg ; 107: 623-629, 2017 Nov.

Artigo em Inglês | MEDLINE | ID: mdl-28842232

6.

Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.

Ruane, Peter; Lang, Joseph; DeJesus, Edwin; Berger, Daniel S; Dretler, Robin; Rodriguez, Allan; Ward, Douglas J; Lim, Michael L; Liao, Qiming; Reddy, Sunila; Clair, Marty St; Vila, Tania; Shaefer, Mark S.

HIV Clin Trials ; 7(5): 229-36, 2006.

Artigo em Inglês | MEDLINE | ID: mdl-17162316

7.

A new era in HCV treatment.

Berger, Daniel S.

Posit Aware ; 23(3): 42-3, 2011.

Artigo em Inglês | MEDLINE | ID: mdl-21776910

8.

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens.

Swindells, Susan; Cohen, Calvin J; Berger, Daniel S; Tashima, Karen T; Liao, Qiming; Pobiner, Bonnie F; Snidow, Jerry W; Pakes, Gary E; Hernandez, Jaime E.

BMC Infect Dis ; 5: 23, 2005 Apr 08.

Artigo em Inglês | MEDLINE | ID: mdl-15819974

9.

The biography of an HIV doctor. A 20-year retrospective.

Berger, Daniel S.

Posit Aware ; 20(1): 43-5, 2009.

Artigo em Inglês | MEDLINE | ID: mdl-19205097

10.

We mourn our great loss. Paying homage to Martin Delaney. 1945-2009.

Berger, Daniel S.

Posit Aware ; 20(2): 16-7, 2009.

Artigo em Inglês | MEDLINE | ID: mdl-19280740

11.

Sexual encounters with undetectable HIV-positive men. A controversy about HIV transmission.

Berger, Daniel S.

Posit Aware ; 19(6): 59-61, 2008.

Artigo em Inglês | MEDLINE | ID: mdl-19062412

12.

Comparing two integrase inhibitors. The first head-to-head study comparing raltegravir and elvitegravir.

Berger, Daniel S.

Posit Aware ; 19(5): 49-51, 2008.

Artigo em Inglês | MEDLINE | ID: mdl-18831079

13.

Syphilis complications after starting treatment for HIV. One patient's story.

Berger, Daniel S.

Posit Aware ; 18(4): 36-7, 2007.

Artigo em Inglês | MEDLINE | ID: mdl-17682282

14.

A new approach: immune-based treatments against HIV.

Berger, Daniel S.

Posit Aware ; 18(3): 43-4, 2007.

Artigo em Inglês | MEDLINE | ID: mdl-17526118

15.

The importance of being earnest. Specific advantages and new treatment options for the un-undetectable.

Berger, Daniel S.

Posit Aware ; 18(2): 37, 2007.

Artigo em Inglês | MEDLINE | ID: mdl-17390490

16.

The dawn of a new treatment. A look at experimental HIV integrase inhibitors.

Berger, Daniel S.

Posit Aware ; 17(3): 44-5, 2006.

Artigo em Inglês | MEDLINE | ID: mdl-16791964

17.

A new era in HIV treatment: the entry inhibitors.

Berger, Daniel S.

Posit Aware ; 16(1): 51-3, 2005.

Artigo em Inglês | MEDLINE | ID: mdl-17390505

18.

New protease inhibitor TMC-114. Preliminary 24-week late breaker results of the phase II trial.

Berger, Daniel S.

Posit Aware ; 16(2): 27, 41, 2005.

Artigo em Inglês | MEDLINE | ID: mdl-15828108

19.

Minocycline shown to have protection for the brain against HIV. Results of a preclinical study recently published in JAMA.

Berger, Daniel S.

Posit Aware ; 16(4): 49-50, 2005.

Artigo em Inglês | MEDLINE | ID: mdl-16110546

20.

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.

Lennox, Jeffrey L; Dejesus, Edwin; Berger, Daniel S; Lazzarin, Adriano; Pollard, Richard B; Ramalho Madruga, Jose Valdez; Zhao, Jing; Wan, Hong; Gilbert, Christopher L; Teppler, Hedy; Rodgers, Anthony J; Barnard, Richard J O; Miller, Michael D; Dinubile, Mark J; Nguyen, Bach-Yen; Leavitt, Randi; Sklar, Peter.

J Acquir Immune Defic Syndr ; 55(1): 39-48, 2010 Sep.

Artigo em Inglês | MEDLINE | ID: mdl-20404738

BVS Doenças Infecciosas e Parasitárias

Informação e Conhecimento para a Saúde

Configurar filtros

Sua seleção (0)

Formato de exportação:

Exportar:

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.

Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.

Endoscopic Third Ventriculostomy in Patients with Neurofibromatosis Type 1: A Multicenter International Experience.

Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.

A new era in HCV treatment.

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens.

The biography of an HIV doctor. A 20-year retrospective.

We mourn our great loss. Paying homage to Martin Delaney. 1945-2009.

Sexual encounters with undetectable HIV-positive men. A controversy about HIV transmission.

Comparing two integrase inhibitors. The first head-to-head study comparing raltegravir and elvitegravir.

Syphilis complications after starting treatment for HIV. One patient's story.

A new approach: immune-based treatments against HIV.

The importance of being earnest. Specific advantages and new treatment options for the un-undetectable.

The dawn of a new treatment. A look at experimental HIV integrase inhibitors.

A new era in HIV treatment: the entry inhibitors.

New protease inhibitor TMC-114. Preliminary 24-week late breaker results of the phase II trial.

Minocycline shown to have protection for the brain against HIV. Results of a preclinical study recently published in JAMA.

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.